2 months ago
SRRK
AnalystsAllison BratzelAllison Bratzel's Stock Forecasts
AnalystsAllison Bratzel
Sectors:
Industries:
Analyst Ranking
Top 14%
#735 out of 5550 analysts
Average Return
+18.75%
Win Rate
55%32 out of 58
Risk vs Reward
Poor
Good
Allison Bratzel's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Inozyme Pharma IncINZY | +277.36% | $1.06 | $4.00 | 2025-03-11 - 2025-07-01 | Strong Buy |
Tyra Biosciences IncTYRA | +242.21% | $9.76 | $33.40 | 2025-05-21 - 2026-05-20 | Strong Buy |
Replimune Group IncREPL | +154.11% | $6.93 | $17.61 | 2026-02-05 - 2026-10-30 | Strong Buy |
Scholar Rock Holding CorpSRRK | +121.87% | $15.00 | $33.28 | 2024-03-26 - 2025-03-25 | Strong Buy |
Ionis Pharmaceuticals IncIONS | +87.59% | $37.23 | $69.84 | 2024-11-14 - 2025-11-13 | Strong Buy |
Allison Bratzel Analyst Color
Get additional color on Allison Bratzel's coverage of popular stocks
2 months ago
BMRN
2 months ago
BMRN
2 months ago
ARGX
4 months ago
ABVX
6 months ago
MGTX
7 months ago
TYRA
8 months ago
SRRK
8 months ago
IONS
9 months ago
IONS
9 months ago
ALXO
9 months ago
TYRA
a year ago
MGTX
a year ago
ARGX
a year ago
IONS
a year ago
INCY
a year ago
ARGX
a year ago
IONS
a year ago
ABVX
a year ago
REPL
2 years ago
AKBA
2 years ago
ARGX
2 years ago
SRRK
2 years ago
ROIV
3 years ago
ARGX
Allison Bratzel's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Scholar Rock Holding CorpSRRK | 6 | Strong Buy | $75.00 | +70.84% | Maintains | 2 months ago |
Biomarin Pharmaceutical IncBMRN | 3 | Strong Buy | $90.00 | +53.82% | Maintains | 2 months ago |
Rigel Pharmaceuticals IncRIGL | 3 | Hold | $49.00 | -4.50% | Maintains | 2 months ago |
Incyte CorpINCY | 5 | Strong Buy | $130.00 | +7.98% | Maintains | 2 months ago |
Argenx SeARGX | 16 | Strong Buy | $1,215.00 | +36.08% | Maintains | 2 months ago |
Abivax SaABVX | 2 | Strong Buy | $175.00 | +102.10% | Maintains | 4 months ago |
Engene Therapeutics IncENGN | 2 | Hold | $4.00 | +161.44% | Downgrades | 6 months ago |
Meiragtx Holdings PLCMGTX | 3 | Strong Buy | $30.00 | +216.12% | Maintains | 6 months ago |
Humacyte IncHUMA | 3 | Hold | $1.00 | +143.31% | Maintains | 7 months ago |
Tyra Biosciences IncTYRA | 3 | Strong Buy | $56.00 | +165.78% | Maintains | 7 months ago |
Ionis Pharmaceuticals IncIONS | 5 | Strong Buy | $100.00 | +129.78% | Maintains | 8 months ago |
Travere Therapeutics IncTVTX | 4 | Hold | $38.00 | -24.59% | Maintains | 9 months ago |
Akebia Therapeutics IncAKBA | 2 | Strong Buy | $4.00 | +465.77% | Maintains | 9 months ago |
Replimune Group IncREPL | 3 | Strong Buy | $14.00 | -20.50% | Maintains | 9 months ago |
Alx Oncology Holdings IncALXO | 1 | Strong Buy | $4.00 | +227.87% | Maintains | 9 months ago |
Io Biotech IncIOBTQ | 2 | Hold | $0.50 | +941.67% | Downgrades | 9 months ago |
Ultragenyx Pharmaceutical IncRARE | 1 | Strong Buy | $115.00 | N/A | Maintains | 2 years ago |
Inozyme Pharma IncINZY | 1 | Strong Buy | $23.00 | N/A | Maintains | 2 years ago |
Roivant Sciences LtdROIV | 2 | Strong Buy | $22.00 | N/A | Maintains | 2 years ago |
Solid Biosciences IncSLDB | 4 | Strong Buy | $20.00 | N/A | Upgrades | 3 years ago |
Abcellera Biologics IncABCL | 1 | Strong Buy | $20.00 | N/A | Assumes | 3 years ago |
Vectivbio Holding AgVECT | 1 | Strong Buy | $25.00 | N/A | Maintains | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.